ShockWave Medical (SWAV)
(Delayed Data from NSDQ)
$330.38 USD
+0.38 (0.12%)
Updated May 3, 2024 04:00 PM ET
After-Market: $330.38 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$330.38 USD
+0.38 (0.12%)
Updated May 3, 2024 04:00 PM ET
After-Market: $330.38 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Zacks News
Acadia (ACHC) Starts Construction of Malden's JV Facility
by Zacks Equity Research
Acadia Healthcare (ACHC) initiates the construction work of the 144-bed Massachusetts-based joint venture hospital in a bid to address the need for efficient behavioral health services in the region.
Shockwave Medical (SWAV) Up on Potential Acquisition Rumors
by Zacks Equity Research
Shockwave Medical's (SWAV) shares gain as rumors about its potential acquisition by an industry giant get media attention.
Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024
by Nalak Das
We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.
Humana (HUM) Inks Value-Based Deal to Offer Better Kidney Care
by Zacks Equity Research
Humana (HUM) expands ties with Strive to offer high-quality kidney care to its Medicare Advantage members and thereby, aims to increase the customer base of the relevant business line.
Reasons to Add ShockWave Medical (SWAV) to Your Portfolio Now
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
What Makes Shockwave Medical (SWAV) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Shockwave Medical (SWAV) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Invesco S&P MidCap 400 GARP ETF (GRPM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for GRPM
Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for GRPM
Shockwave Medical (SWAV) Q4 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Shockwave Medical's (SWAV) fourth-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.
Shockwave Medical (SWAV) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 26.09% and 1.47%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Shockwave Medical (SWAV) Surges 7.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
Shockwave Medical (SWAV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio Now
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Shockwave Medical (SWAV) Down 1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Shockwave Medical (SWAV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Implied Volatility Surging for ShockWave Medical (SWAV) Stock Options
by Zacks Equity Research
Investors need to pay close attention to ShockWave Medical (SWAV) stock based on the movements in the options market lately.
Shockwave Medical (SWAV) Q3 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Shockwave Medical's (SWAV) third-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.
Shockwave Medical (SWAV) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 13.58% and 0.64%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
DaVita (DVA) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Improvement in U.S. dialysis treatments per day and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the third quarter.
Should You Buy ShockWave Medical (SWAV) Ahead of Earnings?
by Zacks Equity Research
ShockWave Medical (SWAV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Shockwave Medical (SWAV) Crossed Above the 50-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?
Lantheus (LNTH) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Lantheus' (LNTH) third-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.
Shockwave Medical (SWAV) Just Overtook the 20-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
Charles River (CRL) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Charles River's (CRL) CRADLE initiative and research models in North America and China are anticipated to have maintained their growth momentum in the third quarter.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
What's in Store for Cardinal Health (CAH) in Q1 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) first-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical segment.